Conmed (CNMD) Tops Q2 EPS by 9c, Offers Guidance

Conmed (NASDAQ: CNMD) reported Q2 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $255.2 million versus the consensus estimate of $248.31 million.

GUIDANCE:

Conmed sees FY2021 EPS of $3.15-$3.25, versus the consensus of $3.15. Conmed sees FY2021 revenue of $1.02-1.04 billion, versus the consensus of $1.02 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Traws Pharma (TRAW) Tops Q2 EPS by 27c
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30